The PAI-1 4G/5G and ACE I/D polymorphisms and risk of recurrent pregnancy loss: a case-control study

Am J Reprod Immunol. 2014 Dec;72(6):571-6. doi: 10.1111/aji.12302. Epub 2014 Jul 31.

Abstract

Problem: Thrombophilia has been postulated to be a contributor to the pathophysiology of recurrent pregnancy loss (RPL). We investigated the role of the plasminogen activator inhibitor type 1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D polymorphisms in Korean patients with RPL.

Method of study: Genotyping was performed using the TaqMan assay in 227 RPL patients and 304 controls.

Results: The genotype distributions of both polymorphisms in the RPL group did not differ from those of controls. Because the frequency of being homozygous for ACE D/D and the PAI-I 4G/4G combination has been reported to be significantly higher in RPL patients, this was also analyzed. However, no significant difference was noted; 3.1% of RPL patients had both ACE D/D and PAI-I 4G/4G, as did 4.9% of controls (P = 0.791).

Conclusion: The current study suggests that both polymorphisms, either alone or in combination, are not major determinants of the development of RPL in Korean women.

Keywords: Angiotensin converting enzyme; plasminogen activator inhibitor type 1; recurrent pregnancy loss; single-nucleotide polymorphisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Habitual / genetics*
  • Abortion, Habitual / immunology*
  • Adult
  • Case-Control Studies
  • DNA Mutational Analysis
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Middle Aged
  • Peptidyl-Dipeptidase A / genetics*
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic
  • Pregnancy
  • Republic of Korea

Substances

  • Plasminogen Activator Inhibitor 1
  • Peptidyl-Dipeptidase A